Protalix BioTherapeutics, Inc. (PLX)
About Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $52.7M
- Net income
- -$6.6M
- Total assets
- $82.3M
- Market cap
- $160.3M
- Gross margin
- 48.8%
- Operating margin
- -10.4%
- Net margin
- -12.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $52.7M
- Cost of revenue
- $27.0M
- Gross profit
- $25.8M
- Operating expenses
- $31.3M
- Operating income
- -$5.5M
- Income tax
- $996.0K
- Net income
- -$6.6M
- EPS (basic)
- $-0.08
- EPS (diluted)
- $-0.08
Balance sheet
- Total assets
- $82.3M
- Current assets
- $66.7M
- Total liabilities
- $34.1M
- Current liabilities
- $26.5M
- Shareholders’ equity
- $48.2M
Cash flow
- Operating cash flow
- -$12.0M
- Investing cash flow
- -$2.4M
- Financing cash flow
- $9.3M
- Net cash flow
- -$5.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $160.3M
- EPS (diluted)
- $-0.08
- Shares outstanding
- 67.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 2, 1996
Protalix BioTherapeutics, Inc. (PLX) Stock Price
- Reported a net loss of $6.6M in FY2025.
- Revenue grew 38% from FY2021 to FY2025.
- Gross margin of 48.8%, net margin -12.5%.
- Trading 25% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Protalix BioTherapeutics, Inc..
Write a review
News about Protalix BioTherapeutics, Inc.
News & sentiment via Polygon.io
Protalix BioTherapeutics, Inc.: frequently asked questions
Is Protalix BioTherapeutics, Inc. an American company?
Protalix BioTherapeutics, Inc. is a US-based company headquartered in Hackensack, New Jersey, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Protalix BioTherapeutics, Inc. headquartered?
Protalix BioTherapeutics, Inc. is headquartered in Hackensack, New Jersey, United States.
Is Protalix BioTherapeutics, Inc. publicly traded?
Yes — Protalix BioTherapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol PLX on the NYSE.
What does Protalix BioTherapeutics, Inc. do?
Protalix BioTherapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
